|
Market Closed -
Euronext Paris
18:55:00 21/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.8100 EUR | +0.25% |
|
-5.81% | +16.71% |
| 07-22 | Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications | CI |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 22.37M | - | ||||
| 72.12B | |||||
| 65.85B | |||||
| 29.28B | - | ||||
| 27.47B | - | ||||
| 26.7B |
- Stock Market
- Stocks
- ALVAL Stock
- Charts Valbiotis
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
